AU2021306424A1 - Compositions and methods for the treatment of obstructive sleep apnoea (OSA) - Google Patents

Compositions and methods for the treatment of obstructive sleep apnoea (OSA) Download PDF

Info

Publication number
AU2021306424A1
AU2021306424A1 AU2021306424A AU2021306424A AU2021306424A1 AU 2021306424 A1 AU2021306424 A1 AU 2021306424A1 AU 2021306424 A AU2021306424 A AU 2021306424A AU 2021306424 A AU2021306424 A AU 2021306424A AU 2021306424 A1 AU2021306424 A1 AU 2021306424A1
Authority
AU
Australia
Prior art keywords
minutes
pharmaceutically acceptable
thc
acceptable salt
carbonic anhydrase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021306424A
Other languages
English (en)
Inventor
Sudhanshu Agarwal
Mark Robert BLEACKLEY
Joel Bradley LATHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incannex Healthcare Ltd
Original Assignee
Incannex Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902368A external-priority patent/AU2020902368A0/en
Application filed by Incannex Healthcare Ltd filed Critical Incannex Healthcare Ltd
Publication of AU2021306424A1 publication Critical patent/AU2021306424A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021306424A 2020-07-09 2021-07-09 Compositions and methods for the treatment of obstructive sleep apnoea (OSA) Pending AU2021306424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902368 2020-07-09
AU2020902368A AU2020902368A0 (en) 2020-07-09 A method of treatment
PCT/AU2021/050734 WO2022006636A1 (en) 2020-07-09 2021-07-09 Compositions and methods for the treatment of obstructive sleep apnoea (osa)

Publications (1)

Publication Number Publication Date
AU2021306424A1 true AU2021306424A1 (en) 2023-01-19

Family

ID=79553355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021306424A Pending AU2021306424A1 (en) 2020-07-09 2021-07-09 Compositions and methods for the treatment of obstructive sleep apnoea (OSA)

Country Status (8)

Country Link
US (1) US20230310364A1 (https=)
EP (1) EP4178568A4 (https=)
JP (1) JP7796718B2 (https=)
AU (1) AU2021306424A1 (https=)
CA (1) CA3182528A1 (https=)
CO (1) CO2023000118A2 (https=)
IL (1) IL299212A (https=)
WO (1) WO2022006636A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025520386A (ja) * 2022-06-21 2025-07-03 アプニメッド，インコーポレイテッド（デラウェア） カンナビノイドおよびカルボニックアンヒドラーゼ阻害剤の組合せを用いた睡眠時無呼吸を治療する方法
EP4626410A1 (en) * 2022-11-29 2025-10-08 Incannex Healthcare Limited A method of treating obstructive sleep apnoea (osa)
WO2025107039A1 (en) * 2023-11-23 2025-05-30 Incannex Healthcare Limited Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule
WO2025191322A1 (en) * 2024-03-11 2025-09-18 Mousavi Mirzaei Seyed Mohammad Therapeutic composition for improving symptoms of obstructive sleep apnea

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
CA3126772A1 (en) * 2018-01-29 2019-08-01 Evero Compositions and methods for treating obstructive sleep apnea
WO2019180706A1 (en) * 2018-03-19 2019-09-26 Bol Pharma Ltd. Methods and compositions for treating epilepsy and associated disorders
US20240189328A1 (en) * 2021-04-16 2024-06-13 Apnimed, Inc. (Delaware) Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea

Also Published As

Publication number Publication date
IL299212A (en) 2023-02-01
CA3182528A1 (en) 2022-01-13
EP4178568A1 (en) 2023-05-17
JP2023533289A (ja) 2023-08-02
WO2022006636A1 (en) 2022-01-13
CO2023000118A2 (es) 2023-04-17
JP7796718B2 (ja) 2026-01-09
EP4178568A4 (en) 2024-10-16
US20230310364A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
US20230310364A1 (en) Compositions and methods for the treatment of obstructive sleep apnoea (osa)
KR20190140019A (ko) 수면 무호흡을 치료하기 위한 방법 및 조성물
WO2007052013A1 (en) A combination of cannabinoids for the treatment of peripheral neurophatic pain
EP3920898B1 (en) Methods and compositions for treating sleep apnea
JP2013516488A (ja) 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療
JP2004532215A (ja) 睡眠時の自律的安定性に関するカンナビノイドの機能的役割
AU2021293178A1 (en) Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
WO2013173317A1 (en) TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
US20240366635A1 (en) Treatment of seizure disorders
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
AU2023404665A1 (en) A method of treating obstructive sleep apnoea (osa)
CN116829135A (zh) 大麻二酚对睡眠呼吸暂停的治疗
US20230135373A1 (en) Methods and compositions for treating sleep apnea
AU2022245235A1 (en) Methods and compositions for treating sleep apnea
WO2025107039A1 (en) Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule
US20220370347A1 (en) Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
MXPA04004380A (es) Tratamiento y prevencion de parestesia que comprende co-terapia con derivados anticonvulsivos y potasio.
Lockhart (834): Topical sterile lidocaine patch to reduce postoperative pain and decrease need for oral analgesics after inguinal herniorrhaphy
WO2025207125A1 (en) Combination pharmacological interventions for obstructive sleep apnea
HK40065333B (en) Methods and compositions for treating sleep apnea
CA3210092A1 (en) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
CN116782891A (zh) 大麻二酚对难治性癫痫发作的治疗
Locketz et al. (833): Broken heart syndrome following acute withdrawal of opioid therapy in the perioperative setting
Hatfield et al. (835): The analgesic properties of oral sucrose: Efficacy and duration during routine immunizations at 2 and 4 months of age
Sutters et al. (832): The effectiveness of a scheduled oral analgesic dosing regimen for the management of postoperative pain in preschool children following tonsillectomy